Insights

The trials behind the numbers.

Plain-English summaries of the STEP 1 and SURMOUNT-1 trials behind GLP-1 weight-loss medications, and notes on how clinician review works at TelePep.

STEP 1 · Wilding et al. · NEJM 2021

A 14.9% average drop on the scale, in just over a year.

What the medication actually delivered on top of lifestyle change — and what that means for an individual.

Read →

SURMOUNT-1 · Jastreboff et al. · NEJM 2022

A 20.9% average drop at the highest dose.

How tirzepatide at its highest trial dose performed across 72 weeks, and why it is studied alongside (not in place of) semaglutide.

Read →

STEP 1 · Wilding et al. · NEJM 2021

86% of participants crossed the threshold that actually matters.

Five percent body-weight loss is the level where blood pressure, blood sugar, and cardiovascular risk start to measurably improve. Most of the semaglutide arm got there.

Read →

Tirzepatide overview

Why tirzepatide is often discussed alongside semaglutide

Tirzepatide is often presented as a next-generation metabolic option because it acts on more than one pathway related to appetite and glucose regulation.

Read →

Care process

How clinician review works in telehealth

What happens between submitting an intake and a prescription decision.

Read →

Patient experience

What creates a high-quality patient experience?

Patient experience is shaped by clarity, follow-up, responsiveness, and confidence in the care path.

Read →

Compliance

These pages are educational and are not medical advice. Trial results describe the FDA-approved products studied, not compounded formulations. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality.